期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 19, 页码 13452-13472出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01394
关键词
-
资金
- National Natural Science Foundation of China [82003572, 91957116, 82030109, 82104261]
- Shanghai Municipal Science and Technology Major Project
- Shanghai Rising-Star Program [20QA1411200]
The intestinal FXR antagonist F6 showed significant anti-inflammatory and anti-fibrotic effects in NASH models and achieved its beneficial effects through direct antagonism of intestinal FXR and feedback activation of hepatic FXR.
Farnesoid X receptor (FXR) has emerged as a promising therapeutic target for nonalcoholic steatohepatitis (NASH) because of its tightly interwoven relationship with bile acid homeostasis, inflammation, fibrosis, and glucose and lipid metabolism. Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and F6 was identified as the most potent one with an IC(50 )at 2.1 mu M. F6 selectively inhibited intestinal FXR signaling and ameliorated the hepatic steatosis, inflammation, and fibrosis in Gubra-amylin NASH (GAN) and high-fat with methionine and choline deficiency (HFMCD) diet-induced NASH models. The beneficial effects were achieved by direct antagonism of intestinal FXR and feedback activation of hepatic FXR, thereby decreasing ceramides and repressing inflammasome activation in the liver. Collectively, our work substantially supports F6 as a promising drug candidate against NASH and demonstrates that antagonism of intestinal FXR signaling is a practical strategy for treating metabolic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据